Celldex Therapeutics (CLDX) Projected to Announce Quarterly Earnings on Monday

Celldex Therapeutics (NASDAQ:CLDX) will likely be issuing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Celldex Therapeutics to post earnings of ($1.02) per share and revenue of $0.72 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.73 million. On average, analysts expect Celldex Therapeutics to post ($4.17) EPS for the current fiscal year and ($4.29) EPS for the next fiscal year.

Celldex Therapeutics Trading Down 0.6%

CLDX opened at $29.93 on Monday. The business’s 50 day moving average is $34.06 and its 200-day moving average is $32.58. The stock has a market cap of $2.35 billion, a PE ratio of -6.92 and a beta of 1.04. Celldex Therapeutics has a twelve month low of $22.10 and a twelve month high of $45.14.

Analysts Set New Price Targets

CLDX has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $64.00 price objective on shares of Celldex Therapeutics in a report on Friday, October 2nd. Wall Street Zen upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Leerink Partners boosted their price target on Celldex Therapeutics from $70.00 to $88.00 and gave the company an “outperform” rating in a research note on Wednesday, September 23rd. Canaccord Genuity Group dropped their target price on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, Barclays upped their price target on Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $63.08.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapeutics for diseases with significant unmet medical needs. The company uses antibody-based technologies to develop treatments intended to modulate the immune system and address inflammatory, autoimmune and other serious conditions.

Celldex’s lead investigational product is barzolvolimab, an antibody designed to selectively block the KIT receptor and reduce mast-cell activity.